Stock Price

With revenue hitting a record $47.6M, TerraCycle proves sustainability is profitable. But as it raises millions, can it overcome greenwashing critiques?

Amid a crisis in the Strait of Hormuz, Heidmar adds five tankers to seize record-high rates, betting on both immediate profits and long-term eco-design.

Dubai-based robotics firm Micropolis AI is under scrutiny after a delayed annual report triggered a warning from the NYSE American exchange.

Newly independent, auto supplier Versigent will meet investors to prove its critical role in powering the EV and autonomous vehicle revolution.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

With M&A veteran Jay Wright taking control, Worldwide NFT is ditching its namesake focus for an aggressive acquisition strategy in AI, robotics, and software.

Newly public Yesway faces its first major test with its Q1 earnings. Investors will scrutinize if its aggressive expansion can meet high analyst expectations.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

The Chinese gaming giant signals confidence with a major share repurchase, but is it a growth strategy or a defensive play in a challenging market?

A pivotal Q4 sees Exicom's consolidated business break even for the first time since its Tritium acquisition, driven by a global turnaround and Indian EV dominance.

With backing from Bain Capital and Armistice, the life sciences firm's latest offering aims to fund its push to automate pharmaceutical quality control.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

Courier giant FlashEx lands a key state-backed investment to accelerate its drone delivery services, positioning Hangzhou as a blueprint for future urban logistics.

Malaysian aquaculture firm Megan Holdings' stock has plummeted, triggering a Nasdaq delisting warning and a six-month race to regain compliance.

The Fortune 250 retailer's 10% dividend hike reflects strong financials and a strategic navigation of a complex, evolving automotive landscape.

As Fabrinet preps for a key J.P. Morgan conference, record revenues clash with supply chain woes, putting its role in the AI revolution under a microscope.

The former solar EV pioneer has completed its radical pivot, selling its solar business to management and betting its entire future on Bitcoin.

TSLX prices a $300M bond offering and plans a strategic swap to manage risk, signaling confidence and enhancing its firepower in private credit.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.